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Abstract
Background: A consensus on the most reliable staging system for hepatocellular carcinoma
(HCC) is still lacking but the most used is a revised Barcelona Clinic Liver Cancer (BCLC) system,
adopted by the American Association for the Study of Liver Diseases (AASLD). We investigated
how many patients are diagnosed in "very early" and "early" stage, follow the AASLD guidelines for
treatment and whether their survival depends on treatment.
Methods:  Data were collected in 530 "very early" and  "early"  HCC patients recruited by a
multicentric Italian collaborative group (ITA.LI.CA). The Kaplan-Meier method was used to
estimate overall survival and the log rank to test the statistical significance of difference between
groups. Cox's multivariate stepwise regression analysis was used to pinpoint independent
prognostic factors and the adjusted relative risks (hazard ratios) were calculated as well. A
statistical analysis based on the chi-square test was used to identify significant differences in clinical
or pathological features between patients. A P-value < 0.05 was considered statistically significant.
Results:  "Very early" HCC were 3%; Cox multivariate analysis did not identify variables
independently associated with survival. The patients following AASLD recommendations (20%) did
not show longer survival. In "early" HCC patients (25%), treatment significantly modulated survival
(p = 0.0001); the 28% patients treated according to the AASLD criteria survived longer (p = 0,004).
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The Cox analysis however identified only age, gender, number of lesions and Child class as
independent predictors of survival.
Conclusion: patients with very early" HCC were very few in this analysis. In most instances they
were not treated with the treatment suggested as the most appropriate by the AASLD guidelines
and the type of treatment had no impact on survival, even though the number of patients was
relatively low and part of the patients were diagnosed before the introduction of the guidelines:
this analysis, therefore, might not be considered as conclusive and should be validated. The "early"
stage group involved more patients, rarely treated according to the guidelines, both overall and also
in those diagnosed after their publication; the survival was in part predicted by the type of
treatment, with better results in those treated according to AASLD indications.
Backgrounds
The last 10 years have seen a proliferation of attempts to
provide HCC patients with reliable staging and prognostic
systems to overcome the inefficiency of the classical
Child-Pugh [1], Okuda [2] and tumor-node-metastasis
(TNM) [3] staging systems. The most reliable and widely
adopted methods for staging HCC are currently the Can-
cer of the Liver Italian Program (CLIP) [4] and BCLC [5]
systems in Europe and the Japan Integrated Staging score
(JIS) in Japan [6]. They have been internally and exter-
nally validated, both retrospectively and prospectively,
and their efficiency has been tested in several clinical and
therapeutic scenarios [6-15]. The BCLC system has
attracted particular attention because it provides not only
a reliable system for staging HCC patients, but also a val-
idated algorithm for the choice of treatment. In the
revised version of the BCLC system, released by the
AASLD [13], patients diagnosed at the best stages are
defined as follows:
- "very early" when single node HCC, smaller than 2 cm, in
Child-Pugh A class, with no symptoms and lack of change
in performance status;
- "early" when single node HCC, smaller than 5 cm, or up
to 3 nodes < 3 cm each, in Child-Pugh A-B class, with no
symptoms and lack of change in performance status.
In the AASLD guidelines, patients with "very early" disease
are candidates for resection, unless they have portal
hypertension and/or increased bilirubin levels, in which
case either liver transplantation or locoregional percuta-
neous treatments are recommended, depending on their
age and associated diseases. Patients with "early" disease,
when presenting portal hypertension or increased
bilirubin that advise against the surgical option, should be
given locoregional treatment or transplant as well.
The aims of this retrospective multi-center study were to
ascertain:
- the proportions of HCC patients presenting with "early"
and "very early" HCC in the cumulative experience of ten Ital-
ian institutions, three of them acting as primary referral cent-
ers and seven as both primary referral and third-level centers;
- how was the management in relation to the AASLD (or
previous BCLC) treatment guidelines;
- whether the choice of treatment really has a crucial
impact on the survival of patients in these two stages,
which is the most effective treatment and whether adher-
ence to the AASLD guidelines has an impact on survival.
Methods
This study retrospectively analyzed data collected prospec-
tively concerning 1834 HCC patients (482 females, 1352
males) recruited from January 1986 to December 2004 at
10 clinical institutions forming the ITA.LI.CA (Italian
Liver Cancer) group. The diagnosis of HCC was histologi-
cally confirmed in 939 cases. In the remainder, it was
based on the guidelines on HCC management, and
obtained by at least two imaging techniques with typical
features for HCC or combining a diagnostic increase in
alfa-fetoprotein (AFP) (> 200 ng/mL) with typical features
detected by one imaging technique [14]. The modality of
cancer diagnosis was defined as "surveillance" when HCC
was detected during routine follow-up (6-monthly or
yearly clinical examination and imaging), "incidental"
when an asymptomatic neoplasm was discovered outside
a surveillance program, and "symptomatic" when HCC
was diagnosed because of the onset of symptoms.
Tumor size and number of lesions were determined on the
basis of the imaging procedures performed, considering
the diameter of the largest lesion in cases of multiple nod-
ules. Tumor stage was determined according to the tumor-
node-metastasis (TNM) [3], and Cancer of the Liver Ital-
ian Program (CLIP) [4] staging systems, as in previous
ITA.LI.CA reports [16,17]. Tumor stage was retrospectively
correlated with the BCLC system [5], given the availability
of reliable data on patients' symptoms and performance
status in the original data base. We considered portal
hypertension (as clinically suggested by the presence of
esophageal varices) or bilirubine level < 2 mg/dl as exclu-
sion criteria for resection.BMC Cancer 2009, 9:33 http://www.biomedcentral.com/1471-2407/9/33
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Virological status regarding hepatitis B virus (HBV) and
hepatitis C virus (HCV) infection was determined on the
basis of routine virological tests. Alcohol abuse was consid-
ered as the long-standing consumption of more than 80 g
ETOH/day in males and 40 g in females. The Child-Pugh
class, the presence of relevant symptoms (ascites, jaundice),
"constitutional syndrome" (fever, weight loss and pain)
or of portal thrombosis, extra-hepatic metastases, or associated
nonhepatic disease, were recorded.
First treatment after diagnosis, i.e. transplantation (OLTx),
surgical RESECTION, radiofrequency-mediated thermal
ablation (RFTA), percutaneous ethanol injection (PEI),
transcatheter arterial chemoembolization (TACE), combi-
nations of different treatments and best supportive care
(BSC) were recorded together with the survival in months
from the time of diagnosis. Treatments for HCC were cho-
sen either in accordance to the guidelines or taking into
account specific neoplastic, clinical and biochemical fea-
tures of each patient. This being a partly retrospective and
partly prospective observational study no attempt was
done to standardize the treatment choice in each center.
The Kaplan-Meier method was used to estimate overall sur-
vival (median and 95% CI), defined as the interval between
HCC diagnosis and death or last follow-up visit. To test the
statistical significance of differences in survival between
groups, the log rank method was utilized. The variables con-
sidered in the Cox's multivariate stepwise regression analysis
to pinpoint independent prognostic factors were:
- age;
- gender;
- etiology;
- tumor size (diameter of largest nodule, scored as: 1 = < 2
cm, 2 = 2–3 cm, 3 = > 3 cm);
- number of lesions (1, 2–3);
- Child-Pugh class (A/B);
- CLIP score (0–3);
- type of treatment (OLTx, RESECTION, RFTA, PEI, TACE,
best supportive care [BSC], others).
An internal validation analysis was also performed in a set
of 100 consecutive "early" HCC patients diagnosed in an
more recent time period (included from January 2002 and
December 2004). This was not done on patients with "very
early" HCC due to the small number of patients available
for the analysis.
The adjusted relative risks (hazard ratios) and their 95%
confidence interval (CI) were calculated for variables
independently correlated with survival. A statistical analy-
sis based on the chi-square test was used to identify signif-
icant differences in clinical or pathological features
between differently treated patients. A P-value < 0.05 was
considered statistically significant.
The software utilized was SPSS 14.0 for Windows.
The ITA.LI.CA database management conformed to the
past and current Italian legislation on the privacy and the
study conformed to the ethical guidelines of the Declara-
tion of Helsinki. The study was approved by the ethic
committee of the participating Institutions.
Results
Based on the above-described AASLD criteria, two groups
of patients were singled out, one with "very early" HCC,
including 65 patients (3% of the whole series), and the
other with "early" HCC, encompassing 465 patients (25%).
Therefore, these patients accounted overall for the 28% of
all cases diagnosed at the units participating in the study.
The features of the two subgroups are given in Tables 1.
Taken together, "very early" and  "early"  HCC patients
showed the following characteristics:
- a median overall survival of 46 months (95% CI 42–50);
- patients with nodes < 2 cm survived significantly longer
(median 65 months, 95% CI 49–80) than those with
nodes 2 to 3 cm (43 months, 95% CI 38–48) or larger
than 3 cm (46 months, 95% CI 41–50, p < 0.001);
- Child A patients had a significantly longer survival
(median 50 months, 95% CI 44–54) than Child B sub-
jects (26 months, 95% CI 21–31, p < 0.0001), irrespective
of tumor size.
"Very early" disease
"Very early" HCCs were more frequently diagnosed in
patients under surveillance (p = 0.002) and survived
longer (median 60 months, 95% CI 47–72) than patients
with "early"  disease (42 months, 95% CI 38–46)(p <
0.003) (Fig. 1). The percentage of "Very early" HCCs did
not increase over time and it was stable at 3% also in the
2002–2004 period, chosen to evaluate any trend.
Among "very early" HCC patients, there was a borderline
(p = 0.06) difference in survival between patients receiv-
ing OLTx, RESECTION, PEI, RFTA, TACE and BSC (Fig. 2).
OLTx gave the best results, with a median survival of 90
months; resection followed with 86 months survival (CIBMC Cancer 2009, 9:33 http://www.biomedcentral.com/1471-2407/9/33
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Table 1: Distribution of "very early" and "early" HCC, according to the different variables.
Very Early HCC (65) Early HCC (465)
Variables N % N %
Gender Male (M) 43 66 316 68
Female (F) 22 34 149 32
Age < 60 16 24 107 23
60 – 70 31 48 214 46
> 70 18 28 144 31
Disease Aetiology HBV 4 6 42 9
HCV 44 68 274 59
Alcohol abuse 7 11 51 11
Alcohol and virus 4 6 56 12
Mixed and others 6 9 42 9
HCC diagnosis Incidental 6 9 116 25
Surveillance 58 89 326 70
Symptomatic 1* 2 23* 5
Alfafetoprotein < 20 ng/ml 31 47 228 49
20–200 ng/ml 27 42 205 44
> 200 ng/ml 7 11 32 7
Bilirubin < 2 mg/dl 62 95 398 85
≥2 mg/dl 3 5 67 15
Lesion number 1 65 100 344 74
2–3 0 0 121 26
Tumor size ≤2 cm 65 100 158 34
2–3 cm 0 0 202 43
> 3 cm 0 0 105 23
Child-Pugh class A6 5 1 0 0 3 3 1 7 1
B0 0 1 3 4 2 9
CLIP score 06 1 9 3 2 4 3 5 2
14 7 1 6 7 3 6BMC Cancer 2009, 9:33 http://www.biomedcentral.com/1471-2407/9/33
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16–156). In this group the survival curves of RFTA and PEI
were considered together, given the small number of
patients for each treatment: they obtained a median sur-
vival of 65 months (CI 54–76). Patients undergoing TACE
had a survival of 60 months (CI 37–83). Only 3 patients
were assigned to BSC, due to old age (> 80 years) (1 pt),
multiple associated pathologies (1 pt) or unknown rea-
sons (1 pt). their median survival was 15 months (CI 6–
43).
However, when the 3 cases treated with OLTx and the 3
cases who underwent BSC are disregarded, then the bor-
derline difference disappears (p = 0.858). Cox's multivar-
iate analysis showed that no variable was independently
associated with survival.
The group of patients treated according to the AASLD rec-
ommendations (20%) did not survive longer than that of
patients treated differently (80%)(the subgrouping is
shown in Table 2).
"Early" disease
In cases of "early" HCC, a significant difference in survival
emerged among patients treated with the different thera-
pies (p = 0.0001, Fig. 3), OLTx patients achieving the best
outcome (mean survival 106 months, 89–124 CI). Surgi-
cal resection obtained a median survival of 52 months (CI
45–58), RFTA of 62 months and PEI of 44 months (CI
37–50). Worse results were reached with TACE, either
alone (median survival 34 months, CI 29–39) or in com-
bination with PEI (median survival 41 months, CI 27–
54). Here again, patients were assigned to BSC due to very
advanced age (> 80 years) (5 pts), multiple comorbidities
(23 pts) or unknown reasons (34 pts), and they got the
worst survival (28 months, CI 17–39).
In an attempt to identify possible causes of the low effi-
cacy of TACE, we found that patients treated with TACE:
- were more often Child B (p = 0.0016): 40% (52/128)
versus 20% (54/275) in the other treatment groups;
- had a higher prevalence of large nodules (> 3 cm) (p <
0.005): 19% (23/128) versus 1% (4/275) in patients on
other treatments.
20 0 4 7 1 0
30 0 8 2
Type of treatment OLTx 3 5 11 2
RESECTION 8 12 75 16
RFTA 14 22 58 12
PEI 20 30 106 23
TACE 17 26 128 28
PEI + TACE - - 25 6
BSC 3 5 62 13
OLTx: orthotopic liver transplantation; RFTA: radiofrequency-mediated thermal ablation;
PEI: percutaneous ethanol injection; TACE: transcatheter arterial chemoembolization; BSC: best supportive care.
Table 1: Distribution of "very early" and "early" HCC, according to the different variables. (Continued)
Survival rate in "very early" and "early" HCC Figure 1
Survival rate in "very early" and "early" HCC. Patients 
with "very early" HCC survived longer (median 60 months, 
95% CI 47–72) than patients with "early" disease (42 months, 
95% CI 38–46). The difference is highly statistically significant 
(p < 0.003).
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We therefore considered the subgroup of patients treated
with TACE and presenting with a Child A cirrhosis and
small nodules (≤ 3 cm), as compared with a group with
similar characteristics but treated with RESECTION, PEI or
RFTA, and there was still a significant difference in sur-
vival, thus confirming that TACE is the treatment coincid-
ing with the worst survival (p < 0.03). However, when we
considered patients treated with TACE and BSC alone,
TACE was linked with a significantly longer survival (p =
0.04).
Finally, potential differences in survival were also sought
by comparing patients treated with radical therapies, that
is RESECTION, RFTA or PEI: the first two treatments
Survival curves in patients with very early HCC treated with different modalities Figure 2
Survival curves in patients with very early HCC treated with different modalities. The difference in survival accord-
ing to treatment is not statistically significant (p = 0.06) [OLTx median survival 90 months; resection 86 months (CI 16–156), 
RFTA and PEI 65 months (CI 54–76), TACE 60 months (CI 37–83), BSC 15 months (CI 6–43)]. (OLTx: orthotopic liver trans-
plantation; RFTA: radiofrequency-mediated thermal ablation; PEI: percutaneous ethanol injection; TACE: transcatheter arterial 
chemoembolization; BSC: best supportive care).
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Table 2: Number of "very early" HCC patients treated in adherence with the AASLD indications.
ACTUAL TREATMENT
AASLD INDICATIONS RESECTION OLTx PEI/RFTA TACE BSC
RESECTION 5 (13%) 1(2%) 24(59%) 10(24%) 1(2%)
OLTx 2(33%) 2(33%) - 2(33%) -
PEI or RFTA 1(7%) - 6(46%) 4(31%) 2(16%)
OLTx: orthotopic liver transplantation; RFTA: radiofrequency-mediated thermal ablation;
PEI: percutaneous ethanol injection; TACE: transcatheter arterial chemoembolization; BSC: best supportive care
AASLD indications for treatment are reported in rows; percentages of patients treated per each modality are calculated on the totality of patients 
having that specific indication.
The adherence to AASLD indication was evaluated when all data were available (60/65 pts – 91%).BMC Cancer 2009, 9:33 http://www.biomedcentral.com/1471-2407/9/33
Page 7 of 12
(page number not for citation purposes)
offered a similar chance of survival (median 52 months
[95% CI 47–57] for RESECTION, median not applicable
for RFTA [survival > 50% at 60 months]) and they pro-
vided a significantly longer survival than PEI (median 36
months [95% CI 28–44]) (p = 0,012). The patients
included in RFTA and RESECTION groups did not
revealed significant differences in terms of Child-Pugh
class or number and size of HCC lesions.
The Cox's multivariate analysis showed that age, gender,
number of lesions and Child-Pugh class were independ-
ent predictors of survival (p = 0,001; p = 0,05; p = 0,012
and p = 0,009, respectively), while the type of treatment
was not. Age increases the death risk by 2% for each year,
male gender by 22%, while lesions number > 1 increases
the death risk by 47% and Child-Pugh class by 70%. Then
again we subgrouped the patients according to whether
their treatment complied with the AASLD algorithm
(Table 3). Over one third of the patients (36%) are treated
with TACE, outside the AASLD indications, and 13%
undergo medical treatment and/or BSC.
Internal validation analysis
Given the risk that the inclusion of patients diagnosed in
such a long time span may lead to a bias due to the differ-
ent approach to the treatment over time, both in terms of
management of HCC (before/after the publication of the
guidelines) and in terms of available therapeutic tech-
niques, an internal validation analysis on a series of about
145 patients consecutively diagnosed in a much more
recent period was introduced. The set of consecutive
patients with "early" HCC included in the internal valida-
tion did not show any statistically significant difference
from the whole series with respect to the baseline charac-
terization (mean age, gender and so on). The statistical
evaluation of the series of "early" HCC patients confirmed:
- the significant difference in survival in relation to the
treatment applied (p = 0.003), with OLTx obtaining the
best survival (79 months), resection and RFTA a median
of 45 months, and BSC the worst results, with 12 months
survival (Table 4);
Survival curves in patients with early HCC Figure 3
Survival curves in patients with early HCC. The difference in survival among groups according to treatment modality is 
highly statistically significant (p = 0.0001) [OLTx mean survival 106 months (CI 89–124); Surgical resection median survival 52 
months (CI 45–58), RFTA 62 months, PEI 44 months (CI 37–50), TACE alone 34 months (CI 29–39), TACE+PEI 41 months 
(CI 27–54), BSC 28 months (CI 17–39)]. (OLTx: orthotopic liver transplantation; RFTA: radiofrequency-mediated thermal 
ablation; PEI: percutaneous ethanol injection; TACE: transcatheter arterial chemoembolization; BSC: best supportive care).
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RESECTION  (75 pts)
PEI     (106 pts)               
PEI and TACE (25 pts)
TACE   (128 pts)             
BSC      (62 pts)              
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- the lack of any significant difference with respect to the
compliance to the AASLD guidelines;
- the role as independent predictors of survival in the COX
multivariate analysis of the two variables that were more
significantly associated with prognosis in the whole series,
i.e. age and Child-Pugh class (p = 0.025 and p = 0.011,
respectively), and, conversely, the lack of a significant
impact of the choice of treatment.
Discussion
The main goals of a staging system for a neoplastic disease
are: 1) to give patients a clear prognostic information; 2)
to enable the comparison of the results of different treat-
ments and 3) to suggest a specific treatment for a given
stage of the disease.
Since the literature contains sound evidence of the validity
of both the CLIP and the BCLC staging system, now
revised in the AASLD guidelines, the claimed superiority
of the BCLC over other similarly-validated systems, such
as the CLIP, would be mostly based on the last of the
above points. Whether or not either of these two systems
is clearly superior, supporters of the BCLC maintain
indeed that this system is the only one to link the patient's
stage with a clear-cut treatment indication.
Generally speaking, the characteristics of patients
recruited at a given center have an influence on the effi-
Table 3: Number of "early" HCC patients treated in adherence with the AASLD guidelines.
ACTUAL TREATMENT
AASLD INDICATIONS RESECTION OLTx PEI/RFTA TACE/
PEI+TACE
BSC
RESECTION 30 (28%) 1 (1%) 44 (40%) 27 (25%) 7 (6%)
OLTx 6 (9%) 6 (9%) 9 (14%) 34 (52%) 11(16%)
PEI or RFTA 32 (13%) 4 (2%) 83 (34%) 88 (36%) 37(15%)
OLTx: orthotopic liver transplantation; RFTA: radiofrequency-mediated thermal ablation; PEI: percutaneous ethanol injection; TACE: transcatheter 
arterial chemoembolization; BSC: best supportive care.
AASLD indications for treatment are reported in rows; percentages of patients treated per each modality are calculated on the totality of patients 
having that specific indication.
The adherence to AASLD indication was evaluated when all data were available (419/465 pts – 90%).
Table 4: Median survival (months) in the 145 patients with "early" HCC of the internal validation analysis according to the type of 
treatment.
Type of treatment N Median survival (months) CI 95%
OLTx 5 79 66.211 91.556
RESECTION 17 45 34,327 53,254
RFTA 46 45 40.394 51.247
PEI 16 37 14.384 59.616
TACE 41 44 34.518 53.482
PEI + TACE 10 36 32.006 39.994
BSC 10 12 9.078 14.922
Total 145 45 40.708 49.292
OLTx: orthotopic liver transplantation; RFTA: radiofrequency-mediated thermal ablation; PEI: percutaneous ethanol injection; TACE: transcatheter 
arterial chemoembolization; BSC: best supportive care.
The difference in survival among treatment groups is statistically significant (p = 0,003). In the COX multivariate analysis however only age and 
Child-Pugh class (p = 0.025 and p = 0.011, respectively) were selected as independent predictors of survival.BMC Cancer 2009, 9:33 http://www.biomedcentral.com/1471-2407/9/33
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ciency of a given staging system. Different staging systems
will be more suitable, depending on where and why they
are used [18]. For instance, it is now generally accepted
that the CLIP system works better for advanced HCC and
the BCLC for early disease undergoing surgery and in non
cirrhotics [19,20]. Therefore, some authors go as far as to
suggest that it might be useful to establish different stag-
ing systems, for patients undergoing resection or other
ablative therapies, and for those undergoing palliative
treatment [12].
For the BCLC staging system, however, the bottom line is:
can we be fully confident that the proposed stage-related
treatment indications are so helpful that adhering to them
will give patients the best possible chances of survival?
Regarding the revised "very early" HCC stage, our results
suggest the following:
1. The proportion of patients with "very early" HCC is only
3% in a large series collected by primary referral centers
involved in recruiting patients with non advanced disease.
As this figure would probably decrease at less experienced
centers, our information makes rather feeble the epidemi-
ological relevance of this stage in clinical practice. It is
doubtful whether the trend toward an earlier diagnosis of
HCC observed in centers where surveillance of cirrhotics
is performed would significantly modify the overall figure
[21], given that this did not happen in our series, at least
until 2004.
2. Survival rates in patients with "very early" HCC are sat-
isfactory irrespective of the type of treatment. In the uni-
variate analysis, the choice of treatment, overall, shows a
borderline impact on survival. However, when patients
who underwent OLTx, that should not be indicated in this
stage of the disease with very few exceptions, and those
who underwent BSC are disregarded, any difference disap-
pears. In the multivariate analyses the choice of treatment
has no impact on survival, even when including BSC.
However, being low the number of patients with "very
early" HCC we might have missed the expected difference
in survival among treatment groups and prospective vali-
dation analysis is needed to define the best treatment in
this subgroup of patients.
3. Finally, the percentage of patients treated according to
the AASLD recommendations was rather small. Since this
result was common to "early" HCCs, it will be commented
later.
The picture is slightly different for patients with "early"
disease, who account for a substantial share of HCCs.
Here the survival was highest after OLTx, therapeutic pro-
cedure performed only in 2% of the patients, possibly as
a result of reduced organ availability, comorbidity or
advanced age. Same considerations apply also to the
group of "very early" HCC. RESECTION followed in terms
of efficacy, then percutaneous treatments, while survival
was lowest in patients treated with TACE or BSC. Actually,
patients treated with TACE were more likely to have larger
tumors and Child B status, with no difference in the
number of nodules, but the difference between TACE,
RESECTION and percutaneous treatments remained even
after correction for these two factors, in patients in Child
A disease and small tumors. Nonetheless, TACE offered a
prognostic advantage with respect to BSC, suggesting that
it still is of some therapeutic value.
Another point much debated in the literature concerns the
comparison between RESECTION and locoregional treat-
ments. This point was not addressed directly in our study
but, by comparing the results of RESECTION, RFTA and
PEI, we found that the first two treatments performed bet-
ter than PEI. This would be, at least in part, in line with
data recently provided by prospective randomized stud-
ies, showing that RESECTION was as effective as percuta-
neous treatments and RFTA superior to PEI [22-25]. Our
retrospective observations just confirm what above and it
is worth bearing in mind, however, that RESECTION has
hitherto been the treatment of choice for patients with
limited disease, though these findings insinuate that rec-
ommending RESECTION in the current practice as the
front-line treatment for patients with "early" (and even
more for those with "very early") HCC is not so confidently
supported by the literature [26].
The above considerations are confirmed by the result of
multivariate Cox's analysis, where the type of treatment
did not emerge as independent predictor of survival,
implying that, in the relatively homogeneous group of
patients with "early" HCC, its prognostic impact is over-
come by that of other more powerful factors, e.g. age, gen-
der, Child-Pugh class and tumor burden.
In a recent work, Wang et al analyzed a large cohort of
patients to assess the impact on survival of treatment
choice in the different BCLC stages [27]. A clear-cut differ-
ence in survival with respect of the therapeutic option was
found for "early" HCC patients, as well as in our study; for
"very early" HCC patients the Authors reported a border-
line significance for the decreasing linear trend in survival,
with a distinct difference between surgery and TACE, but
not between surgery and percutaneous treatments. Fur-
thermore, as the Authors state, the analysis presents some
limitations, both in the stage assignation of patients and
in the choice of treatment (for instance, no patients were
transplanted, and very few underwent percutaneous abla-
tion), so that the results can not be considered as conclu-
sive. In any case, also in their experience, the percentage ofBMC Cancer 2009, 9:33 http://www.biomedcentral.com/1471-2407/9/33
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patients with "very early" HCC was negligible (3%), as in
our series.
An additional point to make is that the percentage of
patients with "early"  disease treated according to the
AASLD guidelines, albeit higher than in "very early" HCC,
remained relatively small. While for "very early" HCC no
survival benefit was found for patients treated according
to the guidelines, in "early" HCC the difference between
the two subgroups was statistically significant, but again,
without being identified in the multivariate analysis as an
independent predictor of survival.
Our study presents some limitations, due to the wide time
interval of patients recruitment: it is well-known that in
recent years diagnostic and therapeutic techniques have
significantly developed, leading to a wider identification
of early HCC stages and allowing more frequently the
application of radical treatments. Furthermore, our data
collection began before the publication of BCLC staging
system, and this may have influenced our results.
Being aware of this and in order to minimize any bias, an
internal validation analysis was carried out in a series of
100 consecutive "early"  HCC patients, diagnosed in a
more recent period: even in this case the principal data
obtained in the whole patients group were basically con-
firmed.
Why do so few centres follow the AASLD recommenda-
tions? We can suggest three explanations:
1) Our series was recruited before the emanation of
AASLD guidelines and, although its therapeutic algorithm
had been proposed before by the Barcelona group, it was
still under debate and revision. Indeed, most ITA.LI.CA
clinicians followed the Italian guidelines [14] which had
been available earlier. We tried to limit this bias selecting
a more appropriate series of patients, but further valida-
tion analysis on recent years may be useful to understand
how much the application of the guidelines is different
from our results.
2) The experience matured in clinical practice could have
suggested that "very early" HCC occurring in well compen-
sated patients can be efficiently treated with different
approaches. In line with our result, a recent randomized
controlled trial has shown that RESECTION and PEI
ensure the same survival to cirrhotic patients with one or
two nodules ≤2 cm each [28].
3) Finally, the therapeutic choice concerning "early"
tumors stems from the day-to-day experience gained by
operators who evaluate the position and boundaries of
the HCC node(s), the extent of vascularization and portal
hypertension, concomitant diseases, the patient's age or
will, local expertise and resources.
This may have produced the gap between theoretically
ideal and real-life treatment decisions. Even though, gen-
erally speaking, guidelines should not be considered as
mandatory advices, should we try harder to stick to the
AASLD recommendations? Based on the outcome of this
study, it is hard to say.
Conclusion
In short, the data deriving from this analysis of one of the
largest available databases on HCC demonstrate that:
- patients with "very early" HCC are presently very few,
probably too few to make a definition of this stage of the
disease clinically useful. As recently suggested however
[29], the situation might change since we foresee a larger
share of HCC patients diagnosed in this stage as a result of
the wide implementation of surveillance programs, at
least in the western world. With some caution needed in
the evaluation of this set of data, given the relatively small
number of patients included, the survival rates in these
patients are satisfactory not only with OLTx, resection and
RFTA [30], but whatever the treatment, in contrast with
some previous reports, so that the stage-treatment link
appears to be of little consequence;
- patients with "early" disease are a relatively sizable share
of all HCC patients diagnosed. For them using the AASLD
guidelines coincides with better survival; as for the types
of treatment, these can be placed in order of efficiency,
with OLTx at the top and TACE, generally used in patients
with more advanced disease, at the bottom. Nevertheless,
the treatment type and the adherence to the AASLD thera-
peutic algorithm appear to be less important in predicting
survival than patient's age, gender, number of nodes (i.e.
tumor burden) and Child-Pugh class (i.e. liver function).
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